IBIO INC. news, videos and press releases
For more news please use our advanced search feature.
IBIO INC. - More news...
IBIO INC. - More news...
- iBio to Begin Trading on the Nasdaq Stock Exchange
- iBio Reports Fiscal Second Quarter 2025 Financial Results
- iBio Announces New Investments from Board Members and Officers
- iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
- iBio Strengthens Board with Appointment of Two New Independent Directors
- iBio Reports Fiscal First Quarter 2025 Financial Results
- iBio and AstralBio Provide Update on Myostatin Program for Obesity
- iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
- iBio to Participate in Upcoming Investor Conferences
- iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
- iBio Closes Sale of Manufacturing Facility in Texas
- iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
- iBio Announces $15.0 Million Private Placement
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
- iBio Announces Participation in 23rd Annual PepTalk Conference
- iBio Amends and Extends Maturity of Credit Agreement
- Thinking about buying stock in Mongodb, Aquestive Therapeutics, Sovos Brands, Travere Therapeutics, or Ibio Inc?
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering
- iBio Announces Reverse Stock Split
- iBio Explains Recent Filing of Registration Statement
- iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
- iBio Announces Amendment to Credit Agreement with Woodforest
- iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
- iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
- iBio Forges Research Collaboration with the National Institutes of Health
- iBio to Participate in the JMP Securities Life Sciences Conference
- iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
- iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
- Thinking about buying stock in Blackboxstocks, Exela Technologies, iBio, Powerbridge Technologies, or Luminar Technologies?
- Thinking about buying stock in iBio, Jasper Therapeutics, BioSig Technologies, DraftKings, or Eos Energy?
